Delivering Value Beyond the Trial with Real-World Evidence

EP: 1.Current Perspective on Pricing and Reimbursement Models

EP: 2.Overcoming Regulatory Barriers to Market Access

Now Viewing

EP: 3.Delivering Value Beyond the Trial with Real-World Evidence

EP: 4.Aligning Real-World Evidence with Payer Perspectives

EP: 5.Navigating Market Entry Challenges for Orphan Drugs

EP: 6.Effective Tactics for Pricing and Reimbursement in Today’s Market

EP: 7.Designing Effective Value-Based Contracts: Timing, Evidence, and Risk Alignment

EP: 8.Planning for Market Sustainability Under New Policy Frameworks

EP: 9.Rethinking Go-to-Market Strategy with Innovation in a Patient-Centric Era

Real-world evidence (RWE) is no longer optional—it's expected. This episode dives into how payers assess RWE alongside clinical trial data, especially in competitive therapeutic areas. The panel stresses the importance of linking RWE to financial outcomes and making data relevant to specific patient populations. It's not just about data quality; it's about context and credibility.

Key discussion topics include:

• How payers evaluate the financial impact of real-world evidence.
• Distinguishing clean trial populations and diverse real-world patients.
• Using AI to identify high-response patient populations and refine access.
• The role of health equity and demographic alignment in data credibility.